Challenging the current approaches to multiple myeloma-related bone disease: From bisphosphonates to target therapy

Current Cancer Drug Targets

Volumn 9, Issue 7, 2009, Pages 854-870

  Tassone, P ^a   Tagliaferri, P ^a   Rossi, M ^a   Calimeri, T ^a   Bulotta, A ^a   Abbruzzese, A ^b   Caraglia, M ^b   Neri, P ^a,c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 011; ANABOLIC AGENT; ATIPRIMOD; BELINOSTAT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHEMOKINE RECEPTOR ANTAGONIST; CLODRONIC ACID; DENOSUMAB; EPOXOMICIN; ETIDRONIC ACID; I KAPPA B KINASE INHIBITOR; IBANDRONIC ACID; LENALIDOMIDE; LY 2228820; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MLN 120B; MLN 3897; PAMIDRONIC ACID; POMALIDOMIDE; PROTEASOME INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE DISEASE; BONE PAIN; CLINICAL TRIAL; DNA MICROARRAY; DOSE RESPONSE; DRUG CLEARANCE; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; FATIGUE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FAILURE; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OSTEOLYSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; PROTEOMICS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICE, SCID; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 72849146885     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909789760393     Document Type: Review

References (166)

1. Caers, J.; Vande broek, I.; De Raeve, H.; Michaux, L.; Trullemans, F.; Schots, R.; Van Camp, B.; Vanderkerken, K. Multiple myeloma - an update on diagnosis and treatment. Eur. J. Haematol. 2008, 81, 329-343.
2. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. Blood 2008, 111, 2962-2972.
3. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 2004, 351, 1860-1873.
4. Roodman, G. D. Pathogenesis of myeloma bone disease. Leukemia 2008, 23(3), 435-441.
5. Saad, F.; Lipton, A.; Cook, R.; Chen, Y. M.; Smith, M.; Coleman, R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110, 1860-1867. (Pubitemid 47557312)
6. Edwards, C. M.; Zhuang, J.; Mundy, G. R. The pathogenesis of the bone disease of multiple myeloma. Bone 2008, 42, 1007-1013.
7. Radl, J.; De Glopper, E. D.; Schuit, H. R.; Zurcher, C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J. Immunol. 1979, 122, 609-613. (Pubitemid 9089221)
8. Vanderkerken, K.; De Raeve, H.; Goes, E.; Van Meirvenne, S.; Radl, J.; Van Riet, I.; Thielemans, K.; Van Camp, B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br. J. Cancer 1997, 76, 451-460. (Pubitemid 27331209)
9. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000.
10. Lentzsch, S.; Rogers, M. S.; LeBlanc, R.; Birsner, A. E.; Shah, J. H.; Treston, A. M.; Anderson, K. C.; D'Amato, R. J. S-3-Aminophthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002, 62, 2300-2305.
11. Dalton, W.; Anderson, K. C. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin. Cancer Res. 2006, 12, 6603-6610.
12. Pilarski, L. M.; Hipperson, G.; Seeberger, K.; Pruski, E.; Coupland, R. W.; Belch, A. R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95, 1056-1065.
13. Yaccoby, S.; Barlogie, B.; Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92, 2908-2913. (Pubitemid 28469106)
14. Tassone, P.; Neri, P.; Carrasco, D. R.; Burger, R.; Goldmacher, V. S.; Fram, R.; Munshi, V.; Shammas, M. A.; Catley, L.; Jacob, G. S.; Venuta, S.; Anderson, K. C.; Munshi, N. C. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005, 106, 713-716. (Pubitemid 40981270)
15. Hideshima, T.; Neri, P.; Tassone, P.; Yasui, H.; Ishitsuka, K.; Raje, N.; Chauhan, D.; Podar, K.; Mitsiades, C.; Dang, L.; Munshi, N.; Richardson, P.; Schenkein, D.; Anderson, K. C. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin. Cancer Res. 2006, 12, 5887-5894.
16. Tassone, P.; Goldmacher, V. S.; Neri, P.; Gozzini, A.; Shammas, M. A.; Whiteman, K. R.; Hylander-Gans, L. L.; Carrasco, D. R.; Hideshima, T.; Shringarpure, R.; Shi, J.; Allam, C. K.; Wijdenes, J.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004, 104, 3688-3696.
17. Araki, K.; Sangai, T.; Miyamoto, S.; Maeda, H.; Zhang, S. C.; Nakamura, M.; Ishii, G.; Hasebe, T.; Kusaka, H.; Akiyama, T.; Tokuda, Y.; Nagai, K.; Minami, H.; Ochiai, A. Inhibition of bonederived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. Int. J. Cancer 2006, 118, 2602-2608.
18. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; Tagliaferri, P.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res. 2005, 11, 4251-4258.
19. Teoh, G.; Urashima, M.; Greenfield, E. A.; Nguyen, K. A.; Lee, J. F.; Chauhan, D.; Ogata, A.; Treon, S. P.; Anderson, K. C. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J. Clin. Invest. 1998, 101, 1379-1388.
20. Tanaka, Y.; Nakayamada, S.; Okada, Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr. Drug Targets Inflamm. Allergy 2005, 4, 325-328.
21. Bataille, R.; Chappard, D.; Marcelli, C.; Dessauw, P.; Sany, J.; Baldet, P.; Alexandre, C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol. 1989, 7, 1909-1914. (Pubitemid 20014340)
22. Michigami, T.; Shimizu, N.; Williams, P. J.; Niewolna, M.; Dallas, S. L.; Mundy, G. R.; Yoneda, T. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000, 96, 1953-1960. (Pubitemid 30661083)
23. Mitsiades, C. S.; Mitsiades, N. S.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 2006, 42, 1564-1573.
24. Hsu, H.; Lacey, D. L.; Dunstan, C. R.; Solovyev, I.; Colombero, A.; Timms, E.; Tan, H. L.; Elliott, G.; Kelley, M. J.; Sarosi, I.; Wang, L.; Xia, X. Z.; Elliott, R.; Chiu, L.; Black, T.; Scully, S.; Capparelli, C.; Morony, S.; Shimamoto, G.; Bass, M. B.; Boyle, W. J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 1999, 96, 3540-3545. (Pubitemid 29168945)
25. Nakagawa, N.; Kinosaki, M.; Yamaguchi, K.; Shima, N.; Yasuda, H.; Yano, K.; Morinaga, T.; Higashio, K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 1998, 253, 395-400. (Pubitemid 29026714)
26. Ehrlich, L. A.; Roodman, G. D. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol. Rev. 2005, 208, 252-266. (Pubitemid 41746397)
27. Dougall, W. C.; Glaccum, M.; Charrier, K.; Rohrbach, K.; Brasel, K.; De Smedt, T.; Daro, E.; Smith, J.; Tometsko, M. E.; Maliszewski, C. R.; Armstrong, A.; Shen, V.; Bain, S.; Cosman, D.; Anderson, D.; Morrissey, P. J.; Peschon, J. J.; Schuh, J. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13, 2412-2424. (Pubitemid 29453612)
28. Wu, X.; Pan, G.; McKenna, M. A.; Zayzafoon, M.; Xiong, W. C.; McDonald, J. M. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J. Bone Miner. Res. 2005, 20, 107-116. (Pubitemid 41716225)
29. Bucay, N.; Sarosi, I.; Dunstan, C. R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H. L.; Xu, W.; Lacey, D. L.; Boyle, W. J.; Simonet, W. S. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12, 1260-1268. (Pubitemid 28213402)
30. Giuliani, N.; Bataille, R.; Mancini, C.; Lazzaretti, M.; Barille, S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98, 3527-3533.
31. Pearse, R. N.; Sordillo, E. M.; Yaccoby, S.; Wong, B. R.; Liau, D. F.; Colman, N.; Michaeli, J.; Epstein, J.; Choi, Y. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 2001, 98, 11581-11586. (Pubitemid 32928771)
32. Terpos, E.; Szydlo, R.; Apperley, J. F.; Hatjiharissi, E.; Politou, M.; Meletis, J.; Viniou, N.; Yataganas, X.; Goldman, J. M.; Rahemtulla, A. Soluble receptor activator of nuclear factor kappaB ligandosteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102, 1064-1069. (Pubitemid 36917805)
33. Croucher, P. I.; Shipman, C. M.; Lippitt, J.; Perry, M.; Asosingh, K.; Hijzen, A.; Brabbs, A. C.; van Beek, E. J.; Holen, I.; Skerry, T. M.; Dunstan, C. R.; Russell, G. R.; Van Camp, B.; Vanderkerken, K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98, 3534-3540.
34. Epstein, J.; Yaccoby, S. The SCID-hu myeloma model. Methods Mol. Med. 2005, 113, 183-190.
35. Menu, E.; Asosingh, K.; Van Riet, I.; Croucher, P.; Van Camp, B.; Vanderkerken, K. Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol. Dis. 2004, 33, 111-119. (Pubitemid 39094717)
36. Vanderkerken, K.; Goes, E.; De Raeve, H.; Radl, J.; Van Camp, B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br. J. Cancer 1996, 73, 1463-1465. (Pubitemid 26235367)
37. Body, J. J.; Facon, T.; Coleman, R. E.; Lipton, A.; Geurs, F.; Fan, M.; Holloway, D.; Peterson, M. C.; Bekker, P. J. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 2006, 12, 1221-1228.
38. Body, J. J.; Greipp, P.; Coleman, R. E.; Facon, T.; Geurs, F.; Fermand, J. P.; Harousseau, J. L.; Lipton, A.; Mariette, X.; Williams, C. D.; Nakanishi, A.; Holloway, D.; Martin, S. W.; Dunstan, C. R.; Bekker, P. J. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97, 887-892.
39. Fizazi, K.; Lipton, A.; Mariette, X.; Body, J. J.; Rahim, Y.; Gralow, J. R.; Gao, G.; Wu, L.; Sohn, W.; Jun, S. Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. J. Clin. Oncol. 2009, 27(10), 1564-1571.
40. Lipton, A.; Steger, G. G.; Figueroa, J.; Alvarado, C.; Solal-Celigny, P.; Body, J. J.; de Boer, R.; Berardi, R.; Gascon, P.; Tonkin, K. S.; Coleman, R. E.; Paterson, A. H.; Gao, G. M.; Kinsey, A. C.; Peterson, M. C.; Jun, S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res. 2008, 14, 6690-6696.
41. Colucci, S.; Brunetti, G.; Rizzi, R.; Zonno, A.; Mori, G.; Colaianni, G.; Del Prete, D.; Faccio, R.; Liso, A.; Capalbo, S.; Liso, V.; Zallone, A.; Grano, M. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004, 104, 3722-3730. (Pubitemid 39564450)
42. Giuliani, N.; Colla, S.; Sala, R.; Moroni, M.; Lazzaretti, M.; La Monica, S.; Bonomini, S.; Hojden, M.; Sammarelli, G.; Barille, S.; Bataille, R.; Rizzoli, V. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002, 100, 4615-4621. (Pubitemid 35429706)
43. Rollins, B. J. Chemokines. Blood 1997, 90, 909-928.
44. del Pozo, M. A.; Sanchez-Mateos, P.; Nieto, M.; Sanchez-Madrid, F. Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway. J. Cell Biol. 1995, 131, 495-508.
45. Kukita, T.; Nomiyama, H.; Ohmoto, Y.; Kukita, A.; Shuto, T.; Hotokebuchi, T.; Sugioka, Y.; Miura, R.; Iijima, T. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab. Invest. 1997, 76, 399-406. (Pubitemid 27157347)
46. Scheven, B. A.; Milne, J. S.; Hunter, I.; Robins, S. P. Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro. Biochem. Biophys. Res. Commun. 1999, 254, 773-778. (Pubitemid 29290544)
47. Choi, S. J.; Cruz, J. C.; Craig, F.; Chung, H.; Devlin, R. D.; Roodman, G. D.; Alsina, M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96, 671-675. (Pubitemid 30463390)
48. Uneda, S.; Hata, H.; Matsuno, F.; Harada, N.; Mitsuya, Y.; Kawano, F.; Mitsuya, H. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br. J. Haematol. 2003, 120, 53-55. (Pubitemid 36056908)
49. Terpos, E.; Politou, M.; Szydlo, R.; Goldman, J. M.; Apperley, J. F.; Rahemtulla, A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br. J. Haematol. 2003, 123, 106-109. (Pubitemid 37222765)
50. Choi, S. J.; Oba, T.; Callander, N. S.; Jelinek, D. F.; Roodman, G. D. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood 2003, 101, 3778-3783.
51. Choi, S. J.; Oba, Y.; Gazitt, Y.; Alsina, M.; Cruz, J.; Anderson, J.; Roodman, G. D. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J. Clin. Invest. 2001, 108, 1833-1841.
52. Oyajobi, B. O.; Franchin, G.; Williams, P. J.; Pulkrabek, D.; Gupta, A.; Munoz, S.; Grubbs, B.; Zhao, M.; Chen, D.; Sherry, B.; Mundy, G. R. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003, 102, 311-319.
53. Roodman, G. D.; Choi, S. J. MIP-1 alpha and myeloma bone disease. Cancer Treat. Res. 2004, 118, 83-100.
54. Vidriales, M. B.; Anderson, K. C. Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies. Mol. Med. Today 1996, 2, 425-431.
55. Masih-Khan, E.; Trudel, S.; Heise, C.; Li, Z.; Paterson, J.; Nadeem, V.; Wei, E.; Roodman, D.; Claudio, J. O.; Bergsagel, P. L.; Stewart, A. K. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 2006, 108, 3465-3471.
56. Lee, J. W.; Chung, H. Y.; Ehrlich, L. A.; Jelinek, D. F.; Callander, N. S.; Roodman, G. D.; Choi, S. J. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103, 2308-2315.
57. Huston, A.; Roodman, G. D. Role of the microenvironment in multiple myeloma bone disease. Future Oncol. 2006, 2, 371-378. (Pubitemid 43960110)
58. Hideshima, T.; Anderson, K. C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2002, 2, 927-937. (Pubitemid 37328894)
59. Klein, B.; Zhang, X. G.; Lu, Z. Y.; Bataille, R. Interleukin-6 in human multiple myeloma. Blood 1995, 85, 863-872.
60. Hallek, M.; Bergsagel, P. L.; Anderson, K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91, 3-21.
61. Klein, B.; Zhang, X. G.; Jourdan, M.; Content, J.; Houssiau, F.; Aarden, L.; Piechaczyk, M.; Bataille, R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989, 73, 517-526. (Pubitemid 19060538)
62. Abe, M.; Hiura, K.; Wilde, J.; Shioyasono, A.; Moriyama, K.; Hashimoto, T.; Kido, S.; Oshima, T.; Shibata, H.; Ozaki, S.; Inoue, D.; Matsumoto, T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104, 2484-2491. (Pubitemid 39331851)
63. Karadag, A.; Oyajobi, B. O.; Apperley, J. F.; Russell, R. G.; Croucher, P. I. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br. J. Haematol. 2000, 108, 383-390. (Pubitemid 30143655)
64. Sati, H. I.; Apperley, J. F.; Greaves, M.; Lawry, J.; Gooding, R.; Russell, R. G.; Croucher, P. I. Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Br. J. Haematol. 1998, 101, 287-295. (Pubitemid 28261116)
65. Abildgaard, N.; Glerup, H.; Rungby, J.; Bendix-Hansen, K.; Kassem, M.; Brixen, K.; Heickendorff, L.; Nielsen, J. L.; Eriksen, E. F. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur. J. Haematol. 2000, 64, 121-129.
66. Solary, E.; Guiguet, M.; Zeller, V.; Casasnovas, R. O.; Caillot, D.; Chavanet, P.; Guy, H.; Mack, G. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am. J. Hematol. 1992, 39, 163-171.
67. Tassone, P.; Galea, E.; Forciniti, S.; Tagliaferri, P.; Venuta, S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int. J. Oncol. 2002, 21, 867-873.
68. Giuliani, N.; Rizzoli, V.; Roodman, G. D. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006, 108, 3992-3996. (Pubitemid 44913267)
69. Ehrlich, L. A.; Chung, H. Y.; Ghobrial, I.; Choi, S. J.; Morandi, F.; Colla, S.; Rizzoli, V.; Roodman, G. D.; Giuliani, N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005, 106, 1407-1414.
70. Roodman, G. D. Treatment strategies for bone disease. Bone Marrow Transplant 2007, 40, 1139-1146.
71. Westendorf, J. J.; Kahler, R. A.; Schroeder, T. M. Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341, 19-39.
72. Fedi, P.; Bafico, A.; Nieto Soria, A.; Burgess, W. H.; Miki, T.; Bottaro, D. P.; Kraus, M. H.; Aaronson, S. A. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 1999, 274, 19465-19472.
73. Grotewold, L.; Ruther, U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J. 2002, 21, 966-975.
74. Kato, M.; Patel, M. S.; Levasseur, R.; Lobov, I.; Chang, B. H.; Glass, D. A., 2nd; Hartmann, C.; Li, L.; Hwang, T. H.; Brayton, C. F.; Lang, R. A.; Karsenty, G.; Chan, L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 2002, 157, 303-314.
75. Mukhopadhyay, M.; Shtrom, S.; Rodriguez-Esteban, C.; Chen, L.; Tsukui, T.; Gomer, L.; Dorward, D. W.; Glinka, A.; Grinberg, A.; Huang, S. P.; Niehrs, C.; Belmonte, J. C.; Westphal, H. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev. Cell 2001, 1, 423-434.
76. Oshima, T.; Abe, M.; Asano, J.; Hara, T.; Kitazoe, K.; Sekimoto, E.; Tanaka, Y.; Shibata, H.; Hashimoto, T.; Ozaki, S.; Kido, S.; Inoue, D.; Matsumoto, T. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106, 3160-3165.
77. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J. D., Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 2003, 349, 2483-2494.
78. Gunn, W. G.; Conley, A.; Deininger, L.; Olson, S. D.; Prockop, D. J.; Gregory, C. A. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006, 24, 986-991.
79. Politou, M. C.; Heath, D. J.; Rahemtulla, A.; Szydlo, R.; Anagnostopoulos, A.; Dimopoulos, M. A.; Croucher, P. I.; Terpos, E. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int. J. Cancer 2006, 119, 1728-1731.
80. Kaiser, M.; Mieth, M.; Liebisch, P.; Oberlander, R.; Rademacher, J.; Jakob, C.; Kleeberg, L.; Fleissner, C.; Braendle, E.; Peters, M.; Stover, D.; Sezer, O.; Heider, U. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur. J. Haematol. 2008, 80, 490-494.
81. Yaccoby, S.; Ling, W.; Zhan, F.; Walker, R.; Barlogie, B.; Shaughnessy, J. D., Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109, 2106-2111.
82. Glass, D. A., 2nd; Bialek, P.; Ahn, J. D.; Starbuck, M.; Patel, M. S.; Clevers, H.; Taketo, M. M.; Long, F.; McMahon, A. P.; Lang, R. A.; Karsenty, G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 2005, 8, 751-764.
83. Spencer, G. J.; Utting, J. C.; Etheridge, S. L.; Arnett, T. R.; Genever, P. G. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 2006, 119, 1283-1296.
84. Pinzone, J. J.; Hall, B. M.; Thudi, N. K.; Vonau, M.; Qiang, Y. W.; Rosol, T. J.; Shaughnessy, J. D., Jr. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113, 517-525.
85. Giuliani, N.; Colla, S.; Morandi, F.; Lazzaretti, M.; Sala, R.; Bonomini, S.; Grano, M.; Colucci, S.; Svaldi, M.; Rizzoli, V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106, 2472-2483.
86. Feliers, D.; Woodruff, K.; Abboud, S. Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma. Br. J. Haematol. 1999, 104, 715-722.
87. Kobayashi, T.; Kronenberg, H. Minireview: transcriptional regulation in development of bone. Endocrinology 2005, 146, 1012-1017.
88. Iwata, M.; Graf, L.; Awaya, N.; Torok-Storb, B. Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. Blood 2002, 100, 1318-1325.
89. Borset, M.; Hjorth-Hansen, H.; Seidel, C.; Sundan, A.; Waage, A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996, 88, 3998-4004.
90. Seidel, C.; Borset, M.; Turesson, I.; Abildgaard, N.; Sundan, A.; Waage, A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998, 91, 806-812.
91. Derksen, P. W.; de Gorter, D. J.; Meijer, H. P.; Bende, R. J.; van Dijk, M.; Lokhorst, H. M.; Bloem, A. C.; Spaargaren, M.; Pals, S. T. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17, 764-774.
92. Iwasaki, T.; Hamano, T.; Ogata, A.; Hashimoto, N.; Kitano, M.;Kakishita, E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br. J. Haematol. 2002, 116, 796-802.
93. Sengupta, S.; Sellers, L. A.; Cindrova, T.; Skepper, J.; Gherardi, E.; Sasisekharan, R.; Fan, T. P. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res. 2003, 63, 8351-8359.
94. Du, W.; Hattori, Y.; Yamada, T.; Matsumoto, K.; Nakamura, T.; Sagawa, M.; Otsuki, T.; Niikura, T.; Nukiwa, T.; Ikeda, Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007, 109, 3042-3049.
95. Hjertner, O.; Torgersen, M. L.; Seidel, C.; Hjorth-Hansen, H.; Waage, A.; Borset, M.; Sundan, A. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999, 94, 3883-3888.
96. Alexandrakis, M. G.; Kyriakou, D. S.; Passam, F. H.; Malliaraki, N.; Vlachonikolis, I. G.; Karkavitsas, N. Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99msestaMIBI scintigraphy and other biochemical markers of disease activity. Hematol. Oncol. 2003, 21, 17-24.
97. Hov, H.; Tian, E.; Holien, T.; Holt, R. U.; Vatsveen, T. K.; Fagerli, U. M.; Waage, A.; Borset, M.; Sundan, A. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur. J. Haematol. 2009, 82, 277-287.
98. Silvestris, F.; Cafforio, P.; Calvani, N.; Dammacco, F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br. J. Haematol. 2004, 126, 475-486.
99. Russell, R. G.; Xia, Z.; Dunford, J. E.; Oppermann, U.; Kwaasi, A.; Hulley, P. A.; Kavanagh, K. L.; Triffitt, J. T.; Lundy, M. W.; Phipps, R. J.; Barnett, B. L.; Coxon, F. P.; Rogers, M. J.; Watts, N. B.; Ebetino, F. H. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N.Y. Acad. Sci. 2007, 1117, 209-257.
100. Frith, J. C.; Monkkonen, J.; Blackburn, G. M.; Russell, R. G.; Rogers, M. J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gammadichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 1997, 12, 1358-1367.
101. Lehenkari, P. P.; Kellinsalmi, M.; Napankangas, J. P.; Ylitalo, K. V.; Monkkonen, J.; Rogers, M. J.; Azhayev, A.; Vaananen, H. K.; Hassinen, I. E. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 2002, 61, 1255-1262.
102. van Beek, E.; Pieterman, E.; Cohen, L.; Lowik, C.; Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 1999, 264, 108-111.
103. Dunford, J. E.; Rogers, M. J.; Ebetino, F. H.; Phipps, R. J.; Coxon, F. P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J. Bone Miner. Res. 2006, 21, 684-694.
104. Fisher, J. E.; Rogers, M. J.; Halasy, J. M.; Luckman, S. P.; Hughes, D. E.; Masarachia, P. J.; Wesolowski, G.; Russell, R. G.; Rodan, G. A.; Reszka, A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 1999, 96, 133-138.
105. Caraglia, M.; D'Alessandro, A. M.; Marra, M.; Giuberti, G.; Vitale, G.; Viscomi, C.; Colao, A.; Prete, S. D.; Tagliaferri, P.; Tassone, P.; Budillon, A.; Venuta, S.; Abbruzzese, A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004, 23, 6900-6913.
106. Tassone, P.; Tagliaferri, P.; Viscomi, C.; Palmieri, C.; Caraglia, M.; D'Alessandro, A.; Galea, E.; Goel, A.; Abbruzzese, A.; Boland, C. R.; Venuta, S. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer 2003, 88, 1971-1978.
107. Tassone, P.; Forciniti, S.; Galea, E.; Morrone, G.; Turco, M. C.; Martinelli, V.; Tagliaferri, P.; Venuta, S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14, 841-844.
108. Salomo, M.; Jurlander, J.; Nielsen, L. B.; Gimsing, P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br. J. Haematol. 2003, 122, 202-210.
109. Muller, S.; Migianu, E.; Lecouvey, M.; Kraemer, M.; Oudar, O. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res. 2005, 25, 2655-2660.
110. Ory, B.; Heymann, M. F.; Kamijo, A.; Gouin, F.; Heymann, D.; Redini, F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104, 2522-2529.
111. Virtanen, S. S.; Vaananen, H. K.; Harkonen, P. L.; Lakkakorpi, P. T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002, 62, 2708-2714.
112. Soltau, J.; Zirrgiebel, U.; Esser, N.; Schachtele, C.; Totzke, F.; Unger, C.; Merfort, I.; Drevs, J. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008, 28, 933-941.
113. Terpos, E.; Rahemtulla, A. Bisphosphonate treatment for multiple myeloma. Drugs Today (Barc) 2004, 40, 29-40.
114. Idris, A. I.; Rojas, J.; Greig, I. R.; Van't Hof, R. J.; Ralston, S. H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif. Tissue Int. 2008, 82, 191-201.
115. Uveges, T. E.; Kozloff, K. M.; Ty, J. M.; Ledgard, F.; Raggio, C. L.; Gronowicz, G.; Goldstein, S. A.; Marini, J. C. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res. 2009, 24, 849-859.
116. Mehrotra, B.; Ruggiero, S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am. Soc. Hematol. Educ. Program 2006, 356-360, 515.
117. Rosen, L. S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.; Coleman, R. E.; Reitsma, D. J.; Seaman, J. J.; Chen, B. L.; Ambros, Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001, 7, 377-387.
118. Rosen, L. S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M. A.; Coleman, R. E.; Reitsma, D. J.; Chen, B. L.; Seaman, J. J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98, 1735-1744.
119. Anderson, K. C.; Alsina, M.; Bensinger, W.; Biermann, J. S.; Chanan-Khan, A.; Comenzo, R. L.; De Castro, C. M.; Djulbegovic, B.; Farag, S.; Huff, C. A.; Meredith, R.; Schriber, J.; Shrieve, D.; Singhal, S.; Smith, M. R.; Stockerl-Goldstein, K.; Vose, J. M.; Weber, D.; Yahalom, J.; Yunus, F. Multiple myeloma. Clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 2007, 5, 118-147.
120. Kyle, R. A.; Yee, G. C.; Somerfield, M. R.; Flynn, P. J.; Halabi, S.; Jagannath, S.; Orlowski, R. Z.; Roodman, D. G.; Twilde, P.; Anderson, K. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 2007, 25, 2464-2472.
121. Terpos, E.; Sezer, O.; Croucher, P. I.; Garcia-Sanz, R.; Boccadoro, M.; San Miguel, J.; Ashcroft, J.; Blade, J.; Cavo, M.; Delforge, M.; Dimopoulos, M. A.; Facon, T.; Macro, M.; Waage, A.; Sonneveld, P. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann. Oncol. 2009, 20, 1303-1317.
122. Dimopoulos, M. A.; Kastritis, E.; Anagnostopoulos, A.; Melakopoulos, I.; Gika, D.; Moulopoulos, L. A.; Bamia, C.; Terpos, E.; Tsionos, K.; Bamias, A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006, 91, 968-971.
123. Anderson, G.; Gries, M.; Kurihara, N.; Honjo, T.; Anderson, J.; Donnenberg, V.; Donnenberg, A.; Ghobrial, I.; Mapara, M. Y.; Stirling, D.; Roodman, D.; Lentzsch, S. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006, 107, 3098-3105.
124. Breitkreutz, I.; Raab, M. S.; Vallet, S.; Hideshima, T.; Raje, N.; Mitsiades, C.; Chauhan, D.; Okawa, Y.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22, 1925-1932.
125. Lai, F. P.; Cole-Sinclair, M.; Cheng, W. J.; Quinn, J. M.; Gillespie, M. T.; Sentry, J. W.; Schneider, H. G. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br. J. Haematol. 2004, 126, 192-201.
126. Boyle, W. J.; Simonet, W. S.; Lacey, D. L. Osteoclast differentiation and activation. Nature 2003, 423, 337-342.
127. Bekker, P. J.; Holloway, D.; Nakanishi, A.; Arrighi, M.; Leese, P. T.; Dunstan, C. R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 2001, 16, 348-360.
128. Bekker, P. J.; Holloway, D. L.; Rasmussen, A. S.; Murphy, R.; Martin, S. W.; Leese, P. T.; Holmes, G. B.; Dunstan, C. R.; DePaoli, A. M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 2004, 19, 1059-1066.
129. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C. P.; Nicholl, J. K.; Sutherland, G. R.; Smith, T. D.; Rauch, C.; Smith, C. A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3, 673-682.
130. Green, L. L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 1999, 231, 11-23.
131. Scallon, B. J.; Moore, M. A.; Trinh, H.; Knight, D. M.; Ghrayeb, J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7, 251-259.
132. Kostenuik, P. J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr. Opin. Pharmacol. 2005, 5, 618-625.
133. Childs, L. M.; Paschalis, E. P.; Xing, L.; Dougall, W. C.; Anderson, D.; Boskey, A. L.; Puzas, J. E.; Rosier, R. N.; O'Keefe, R. J.; Boyce, B. F.; Schwarz, E. M. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J. Bone Miner. Res. 2002, 17, 192-199.
134. Palombella, V. J.; Rando, O. J.; Goldberg, A. L.; Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NFkappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78, 773-785. (Pubitemid 24294453)
135. Garrett, I. R.; Chen, D.; Gutierrez, G.; Zhao, M.; Escobedo, A.; Rossini, G.; Harris, S. E.; Gallwitz, W.; Kim, K. B.; Hu, S.; Crews, C. M.; Mundy, G. R. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 2003, 111, 1771-1782.
136. Ishitsuka, K.; Hideshima, T.; Neri, P.; Vallet, S.; Shiraishi, N.; Okawa, Y.; Shen, Z.; Raje, N.; Kiziltepe, T.; Ocio, E. M.; Chauhan, D.; Tassone, P.; Munshi, N.; Campbell, R. M.; Dios, A. D.; Shih, C.; Starling, J. J.; Tamura, K.; Anderson, K. C. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br. J. Haematol. 2008, 141, 598-606. (Pubitemid 351667613)
137. Terpos, E.; Heath, D. J.; Rahemtulla, A.; Zervas, K.; Chantry, A.; Anagnostopoulos, A.; Pouli, A.; Katodritou, E.; Verrou, E.; Vervessou, E. C.; Dimopoulos, M. A.; Croucher, P. I. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol. 2006, 135, 688-692.
138. Oyajobi, B. O.; Garrett, I. R.; Gupta, A.; Flores, A.; Esparza, J.; Munoz, S.; Zhao, M.; Mundy, G. R. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br. J. Haematol. 2007, 139, 434-438.
139. Giuliani, N.; Morandi, F.; Tagliaferri, S.; Lazzaretti, M.; Bonomini, S.; Crugnola, M.; Mancini, C.; Martella, E.; Ferrari, L.; Tabilio, A.; Rizzoli, V. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110, 334-338. (Pubitemid 47026851)
140. Mukherjee, S.; Raje, N.; Schoonmaker, J. A.; Liu, J. C.; Hideshima, T.; Wein, M. N.; Jones, D. C.; Vallet, S.; Bouxsein, M. L.; Pozzi, S.; Chhetri, S.; Seo, Y. D.; Aronson, J. P.; Patel, C.; Fulciniti, M.; Purton, L. E.; Glimcher, L. H.; Lian, J. B.; Stein, G.; Anderson, K. C.; Scadden, D. T. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 2008, 118, 491-504.
141. Moreaux, J.; Cremer, F. W.; Reme, T.; Raab, M.; Mahtouk, K.; Kaukel, P.; Pantesco, V.; De Vos, J.; Jourdan, E.; Jauch, A.; Legouffe, E.; Moos, M.; Fiol, G.; Goldschmidt, H.; Rossi, J. F.; Hose, D.; Klein, B. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005, 106, 1021-1030. (Pubitemid 41076449)
142. Abe, M.; Kido, S.; Hiasa, M.; Nakano, A.; Oda, A.; Amou, H.; Matsumoto, T. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006, 20, 1313-1315.
143. Neri, P.; Kumar, S.; Fulciniti, M. T.; Vallet, S.; Chhetri, S.; Mukherjee, S.; Tai, Y.; Chauhan, D.; Tassone, P.; Venuta, S.; Munshi, N. C.; Hideshima, T.; Anderson, K. C.; Raje, N. Neutralizing Bcell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 2007, 13, 5903-5909. (Pubitemid 47583918)
144. Lentzsch, S.; Gries, M.; Janz, M.; Bargou, R.; Dorken, B.; Mapara, M. Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003, 101, 3568-3573.
145. Lean, J. M.; Murphy, C.; Fuller, K.; Chambers, T. J. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J. Cell Biochem. 2002, 87, 386-393.
146. Yu, X.; Huang, Y.; Collin-Osdoby, P.; Osdoby, P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J. Bone Miner. Res. 2004, 19, 2065-2077. (Pubitemid 41103422)
147. Oba, Y.; Lee, J. W.; Ehrlich, L. A.; Chung, H. Y.; Jelinek, D. F.; Callander, N. S.; Horuk, R.; Choi, S. J.; Roodman, G. D. MIP- 1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp. Hematol. 2005, 33, 272-278.
148. Moller, C.; Stromberg, T.; Juremalm, M.; Nilsson, K.; Nilsson, G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003, 17, 203-210. (Pubitemid 36175907)
149. Menu, E.; De Leenheer, E.; De Raeve, H.; Coulton, L.; Imanishi, T.; Miyashita, K.; Van Valckenborgh, E.; Van Riet, I.; Van Camp, B.; Horuk, R.; Croucher, P.; Vanderkerken, K. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin. Exp. Metastasis 2006, 23, 291-300. (Pubitemid 44777569)
150. Vallet, S.; Raje, N.; Ishitsuka, K.; Hideshima, T.; Podar, K.; Chhetri, S.; Pozzi, S.; Breitkreutz, I.; Kiziltepe, T.; Yasui, H.; Ocio, E. M.; Shiraishi, N.; Jin, J.; Okawa, Y.; Ikeda, H.; Mukherjee, S.; Vaghela, N.; Cirstea, D.; Ladetto, M.; Boccadoro, M.; Anderson, K. C. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007, 110, 3744-3752.
151. Heath, D. J.; Chantry, A. D.; Buckle, C. H.; Coulton, L.; Shaughnessy, J. D., Jr.; Evans, H. R.; Snowden, J. A.; Stover, D. R.; Vanderkerken, K.; Croucher, P. I. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 2009, 24, 425-436.
152. Qiang, Y. W.; Shaughnessy, J. D., Jr.; Yaccoby, S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008, 112, 374-382.
153. Edwards, C. M.; Edwards, J. R.; Lwin, S. T.; Esparza, J.; Oyajobi, B. O.; McCluskey, B.; Munoz, S.; Grubbs, B.; Mundy, G. R. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008, 111, 2833-2842.
154. Ruckle, J.; Jacobs, M.; Kramer, W.; Pearsall, A. E.; Kumar, R.; Underwood, K. W.; Seehra, J.; Yang, Y.; Condon, C. H.; Sherman, M. L. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J. Bone Miner. Res. 2009, 24, 744-752.
155. Croucher, P. I.; De Hendrik, R.; Perry, M. J.; Hijzen, A.; Shipman, C. M.; Lippitt, J.; Green, J.; Van Marck, E.; Van Camp, B.; Vanderkerken, K. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 2003, 18, 482-492. (Pubitemid 36241065)
156. Edwards, C. M.; Mueller, G.; Roelofs, A. J.; Chantry, A.; Perry, M.; Russell, R. G.; Van Camp, B.; Guyon-Gellin, Y.; Niesor, E. J.; Bentzen, C. L.; Vanderkerken, K.; Croucher, P. I. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int. J. Cancer 2007, 120, 1657-1663.
157. Gordon, S.; Helfrich, M. H.; Sati, H. I.; Greaves, M.; Ralston, S. H.; Culligan, D. J.; Soutar, R. L.; Rogers, M. J. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br. J. Haematol. 2002, 119, 475-483.
158. Coxon, F. P.; Helfrich, M. H.; Larijani, B.; Muzylak, M.; Dunford, J. E.; Marshall, D.; McKinnon, A. D.; Nesbitt, S. A.; Horton, M. A.; Seabra, M. C.; Ebetino, F. H.; Rogers, M. J. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J. Biol. Chem. 2001, 276, 48213-48222. (Pubitemid 37370725)
159. Roelofs, A. J.; Hulley, P. A.; Meijer, A.; Ebetino, F. H.; Russell, R. G.; Shipman, C. M. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int. J. Cancer 2006, 119, 1254-1261.
160. Lawson, M. A.; Coulton, L.; Ebetino, F. H.; Vanderkerken, K.; Croucher, P. I. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochem. Biophys. Res. Commun. 2008, 377, 453-457.
161. Albrightson-Winslow, C. R.; Brickson, B.; King, A.; Olivera, D.; Short, B.; Saunders, C.; Badger, A. M. Beneficial effects of longterm treatment with SK&F 105685 in murine lupus nephritis. J. Pharmacol. Exp. Ther. 1990, 255, 382-387.
162. Neri, P.; Tassone, P.; Shammas, M.; Yasui, H.; Schipani, E.; Batchu, R. B.; Blotta, S.; Prabhala, R.; Catley, L.; Hamasaki, M.; Hideshima, T.; Chauhan, D.; Jacob, G. S.; Picker, D.; Venuta, S.; Anderson, K. C.; Munshi, N. C. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia 2007, 21, 2519-2526. (Pubitemid 350148896)
163. Labrinidis, A.; Diamond, P.; Martin, S.; Hay, S.; Liapis, V.; Zinonos, I.; Sims, N. A.; Atkins, G. J.; Vincent, C.; Ponomarev, V.; Findlay, D. M.; Zannettino, A. C.; Evdokiou, A. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin. Cancer Res. 2009, 15, 1998-2009.
164. Mitsiades, C. S.; Treon, S. P.; Mitsiades, N.; Shima, Y.; Richardson, P.; Schlossman, R.; Hideshima, T.; Anderson, K. C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001, 98, 795-804.
165. Tassone, P.; Tagliaferri, P.; Rossi, M.; Gaspari, M.; Terracciano, R.; Venuta, S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur. J. Cancer 2006, 42, 1530-1538. (Pubitemid 44118767)
166. Bhattacharyya, S.; Epstein, J.; Suva, L. J. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Dis. Markers 2006, 22, 245-255.